Health Care · Biological Products, (No Diagnostic Substances)

MGTX MeiraGTx Holdings plc SEC Filings & Insider Trading Activity 2026

company
CIK 173543897 filings
Russell 2000

MGTX at a glance

MeiraGTx Holdings plc (MGTX, SEC CIK 1735438) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MeiraGTx Holdings plc (MGTX) reported revenue of $81.4 million (up 144.6% from FY2024) and a net loss of $114.2 million. Diluted EPS was -$1.42.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding MeiraGTx Holdings plc (MGTX) shares worth $230.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Forbes Alexandria on November 17, 2026 of 62,000 shares at $8.45 per share.
  • In the last 90 days, MGTX insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$81.4M
+144.6% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$1.4M
13F holders
28 funds
$230.2M · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $4.8M, up $0.4M YoY from $4.4M, driven by Lilly and Reogen services
  • Quarterly net loss $51.3M vs $50.5M; operating loss $49.9M vs $46.1M
  • Best program: AAV-hAQP1 R&D expense $6.2M, up from $2.0M; manufacturing highest at $16.7M
  • Cash, cash equivalents and restricted cash $186.8M; operating cash use $45.3M through nine months
  • Outlook: funding expected into second half of 2028; bota-vec EMA submission planned December 2026 and FDA BLA first quarter 2027

Risk Factors

  • Newly added regulatory risk: EU pharmaceutical reforms adopted September 2026 could change data protection, exclusivity, access obligations and review procedures
  • Most material financial update: Royalty Note Purchase Agreement adds up to $375 million secured obligations, with maturity on June 30, 2036
  • Compliance risk: GDPR violations could trigger fines up to €20 million or 4% of worldwide annual turnover
  • Near-term operational risk: Limited plasmid suppliers and manufacturing capacity could delay clinical trials or commercialization
  • Liquidity risk: $186.8 million in cash, equivalents and restricted cash estimated sufficient into the second half of 2028 with assumptions- Newly added regulatory risk: EU pharmaceutical reforms adopted September 2026 could change data protection, exclusivity, access obligations and review procedures
  • Most material financial update: Royalty Note Purchase Agreement adds up to $375 million secured obligations, with maturity on June 30, 2036
  • Compliance risk: GDPR violations could trigger fines up to €20 million or 4% of worldwide annual turnover
  • Near-term operational risk: Limited plasmid suppliers and manufacturing capacity could delay clinical trials or commercialization
  • Liquidity risk: $186.8 million in cash, equivalents and restricted cash estimated sufficient into the second half of 2028 with assumptions

AI summary of the MGTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Investor focus: review the accompanying press release for revenue, cash position, expenses and pipeline updates

Item EX-99.1: Item EX-99.1

  • Bota-vec MAA submission targeted December 2026, with full FDA BLA expected Q1 2027 and potential commercial launch in late 2027
  • Cash, equivalents and restricted cash $186.8M, with funding projected into H2 2028 including $95.0M Hologen payment and reimbursements
Filed Sep 23, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Alan M. Sebulsky appointed Class I director effective September 23, 2026, serving through the 2028 annual meeting
  • Science and Technology Committee assignment adds biopharmaceutical investment and healthcare industry expertise

Item EX-99.1: Item EX-99.1

  • Board appointment of Alan M. Sebulsky, a healthcare investor with over 40 years’ experience, adds biopharma capital-markets expertise
  • Sebulsky previously oversaw a diversified biopharmaceutical portfolio with over $2 billion in assets at Adage Capital Management

Item 7.01: Regulation FD Disclosure

  • Press release announces Alan M.’s appointment to MeiraGTx leadership
  • Leadership change may affect strategic execution and investor confidence
Filed Aug 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results cover the quarter ended June 30, 2026
  • Press release issued August 13, 2026 and furnished as Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $321.4M and net income $160.7M, driven largely by nonrecurring related-party license and service revenue
  • R&D expense rose to $57.8M from $33.5M, reflecting bota-vec reacquisition and higher AAV2-hAQP1 clinical manufacturing and trial spending

AI summaries of MGTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MGTX

Don't miss the next MGTX filing

  • Alerts as it files. A push when MGTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MGTX, by share count.
  • Ask anything. An AI agent that reads every MGTX filing and answers with sources.

MGTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Forbes AlexandriaSellNov 17, 2026$8.45
Forbes AlexandriaGNov 17, 2026-
Giroux RichardSellOct 20, 2026$9.95
Naylor StuartSellOct 6, 2026$10.64
SEBULSKY ALANASep 23, 2026-
Forbes AlexandriaSellAug 18, 2026$13.86
Giroux RichardSellJul 21, 2026$12.51
Naylor StuartSellJul 7, 2026$14.90

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$33.3M$81.4M
Operating Income--$164.2M-$106.0M
Net Income-$84.0M-$147.8M-$114.2M
Op. Margin--493.4%-130.2%
Net Margin--444.1%-140.3%
Balance Sheet
Total Assets-$269.8M$244.4M
Equity$138.2M$67.8M-$5.8M
ROE-60.8%-217.9%1971.4%
Per Share
EPS$-1.49$-2.12$-1.42
Cash Flow
Operating CF--$104.5M-$46.4M
CapEx$20.2M$5.0M$3.8M

Source: XBRL data in MeiraGTx Holdings plc (MGTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MGTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MGTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$230.2M
Q2 202627$288.2M
Q1 202623$155.5M
Q4 202522$142.1M
Q3 202522$131.7M
Q2 202524$87.4M
Q1 202520$66.6M
Q4 202414$54.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MGTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
4Oct 20, 2026--
4Oct 6, 2026--
4Sep 24, 2026--
8-KSep 23, 2026Analysis-
4Aug 18, 2026--
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Jul 21, 2026--
8-KJul 7, 2026Analysis-
4Jul 7, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--

Related Health Care companies

All Health Care →

MGTX SEC filings: frequently asked questions

Are MGTX insiders buying or selling?

In the last 90 days, MeiraGTx Holdings plc (MGTX) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.4 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MGTX stock?

As of September 30, 2026, the largest MeiraGTx Holdings plc (MGTX) holders among the 13F filers tracked by SignalX were Johnson & Johnson ($73.1 million), BlackRock ($51.4 million), Millennium Management ($30.1 million), State Street Corp ($15.7 million), Goldman Sachs Group ($12.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MGTX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MeiraGTx Holdings plc (MGTX) reported revenue of $81.4 million (up 144.6% from FY2024) and a net loss of $114.2 million. Diluted EPS was -$1.42. The figures come from the XBRL data in the 10-K.

What did MGTX report in its latest 8-K?

MeiraGTx Holdings plc (MGTX) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.

What are the latest MGTX SEC filings?

MeiraGTx Holdings plc (MGTX) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 17, 2026.

What is MGTX's SEC CIK number?

MeiraGTx Holdings plc (MGTX)'s SEC Central Index Key (CIK) is 1735438. EDGAR lists every MGTX filing under that number.

Ask anything about MGTX

The research agent reads MGTX's filings, financials, insider trades and 13F holders, then answers with sources.